28.00
28.00 (0.68%)
As of Mar 06, 2024
Ambrx Biopharma Inc. [AMAM]
Source:
Company Overview
Ambrx Biopharma Inc. is a clinical-stage biologics company focused on discovering and developing a novel class of engineered precision biologics, or EPBs, using our proprietary expanded genetic code technology platform that allows us to incorporate, in a site-specific manner, synthetic amino acids, or SAAs, into proteins within living cells.
| Country | United States |
| Headquarters | la jolla, california |
| Phone Number | (858) 875-2400 |
| Industry | |
| CEO | Daniel J. O’Connor |
| Website | www.clinicaltrials.gov |
Financial Year:
Financial Overview (Dollars in Millions)
| Revenue | $1.1 |
| Operating Profit | $-19.2 |
| Net Income | $-17.8 |
| Net Cash | $172.5 |
Profit Ratios
| Gross Margin | |
| Operating Margin | -1,707 |
| Profit as % of Revenues | |
| Profit as % of Assets | -8.4% |
| Profit as % of Stockholder Equity | -7.1% |
Management Effectiveness
| Return on Equity | -7.1% |
| Return on Assets | -6.4% |
| Turnover Ratio | 0% |
| EBITA |
Balance Sheet and Cash Flow Measures
| Total Assets | $279.9 |
| Total Liabilities | $29.6 |
| Operating Cash Flow | $-26.1 |
| Investing Cash Flow | $38.7 |
| Financing Cash Flow | $159.9 |
